The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: Therapeutic implications

Journal of Neural Transmission

Volumn 119, Issue 2, 2012, Pages 225-234

  Füvesi, Judit ^a   Rajda, Cecilia ^a   Bencsik, Krisztina ^a   Toldi, József ^b   Vécsei, László ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Amyotrophic lateral sclerosis; Inflammation; Kynurenic acid; Multiple sclerosis; Neurodegeneration

Indexed keywords

2 (2 N,N DIMETHYLAMINOETHYLAMINE 1 CARBONYL) 1H QUINOLIN 4 ON; ANTHRANILIC ACID DERIVATIVE; BETA INTERFERON; BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GAMMA INTERFERON; GLATIRAMER; GLUCOSAMIDE KYNURENIC ACID; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON BETA SERINE; KYNURENIC ACID; KYNURENIC ACID DERIVATIVE; KYNURENINE; KYNURENINE AMINOTRANSFERASE; LAQUINIMOD; LEVO 4 CHLOROKYNURENINE; N (3,4) DIMETHOXYCINNAMOYLANTHRANILIC ACID; NATALIZUMAB; OXYGENASE INHIBITOR; PLACEBO; PRODRUG; RILUZOLE; RO 618048; TRYPTOPHAN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; AMYOTROPHIC LATERAL SCLEROSIS; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXCITOTOXICITY; HUMAN; LIPID PEROXIDATION; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRYPTOPHAN METABOLISM;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; HUMANS; KYNURENINE; MULTIPLE SCLEROSIS; NEURAL PATHWAYS; PRODRUGS;

EID: 84857628333     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0765-3     Document Type: Review

References (100)

1. D Alberati-Giani P Ricciardi-Castagloni C Köhler AM Cesura 1996 Regulation of the kynurenine metabolic pathway by interferon-γ in murine cloned macrophages and microglial cells J Neurochem 66 996 1004 8769859 10.1046/j.1471-4159.1996.66030996.x 1:CAS:528:DyaK28Xht1enurk%3D (Pubitemid 26065895)
2. A Amirkhani C Rajda B Arvidsson K Bencsik K Boda E Seres, et al. 2005 Interferon-beta affects the tryptophan metabolism in multiple sclerosis patients Eur J Neurol 12 625 631 16053472 10.1111/j.1468-1331.2005.01041.x 1:STN:280:DC%2BD2MzpsFOisQ%3D%3D (Pubitemid 41117289)
3. Beal MF, Vécsei L (1992) Excitatory amino acids in the pathogenesis of neurodegenerative disorders. In: Vécsei L, Freese A, Swartz KJ, Beal MF (eds) Neurological disorders: novel experimental and therapeutic strategies. Ellis Horwood, Chichester, pp 39-74
4. G Bensimon L Lacomblez V Meininger the ALS/Riluzole study group 1994 A controlled trial of riluzole in amyotrophic lateral sclerosis N Engl J Med 330 585 591 8302340 10.1056/NEJM199403033300901 1:STN:280:DyaK2c7jsVWnsg%3D%3D (Pubitemid 24065791)
5. YM Bordelon MF Chesselet D Nelson F Welsh M Erecinska 1997 Energetic dysfunction in quinolinic acid-lesioned rat striatum J Neurochem 69 1629 1639 9326292 10.1046/j.1471-4159.1997.69041629.x 1:STN:280:DyaK2svmsFGksA%3D%3D (Pubitemid 27406964)
6. N Braidy R Grant S Adams BJ Brew GJ Guillemin 2009 Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons Neurotox Res 16 77 86 19526301 10.1007/s12640-009-9051-z 1:CAS:528:DC%2BD1MXhtVKgsbbK
7. W Cammer 2001 Oligodendrocyte killing by quinolinic acid in vitro Brain Res 896 157 160 11277985 10.1016/S0006-8993(01)02017-0 1:CAS:528: DC%2BD3MXitF2rtrc%3D (Pubitemid 32244159)
8. R Carpenedo A Pittaluga A Cozzi, et al. 2001 Presynaptic kynurenate-sensitive receptors inhibit glutamate release Eur J Neurosci 13 2141 2147 11422455 10.1046/j.0953-816x.2001.01592.x 1:STN:280:DC%2BD3Mzmt1WqsA%3D%3D (Pubitemid 32578800)
9. DM Chari 2007 Remyelination in multiple sclerosis Int Rev Neurobiol 79 589 620 17531860 10.1016/S0074-7742(07)79026-8 1:CAS:528:DC%2BD2sXot1agtbw%3D
10. Y Chen V Meininger GJ Guillemin 2009 Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors Cent Nerv Syst Agents Med Chem 9 32 39 20021336 10.2174/187152409787601941 1:CAS:528:DC%2BD1MXks1WjtLk%3D
11. Y Chen R Stankovich KM Cullen V Meininger B Garner S Coggan, et al. 2010 The kynurenine pathway and inflammation in amyotrophic lateral sclerosis Neurotox Res 18 132 142 19921535 10.1007/s12640-009-9129-7 1:CAS:528: DC%2BC3cXpsVGgsb8%3D
12. Y Chen B Brew GJ Guillemin 2011 Characterization of the kynurenine pathway in NSC-34 cell line: implications for amyotrophic lateral sclerosis J Neurochem 118 816 825 21182524 10.1111/j.1471-4159.2010.07159.x 1:CAS:528:DC%2BC3MXht1eis7nF
13. A Chiarugi A Cozzi C Ballerini L Massacesi F Moroni 2001 Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis Neuroscience 102 687 695 11226705 10.1016/S0306-4522(00)00504-2 1:CAS:528: DC%2BD3MXhsVKlsrs%3D (Pubitemid 32171887)
14. J Chun HP Hartung 2010 Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis Clin Neuropharmacol 33 91 101 20061941 10.1097/WNF. 0b013e3181cbf825 1:CAS:528:DC%2BC3cXksFSgt7g%3D
15. Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E et al, LAQ/5063 Study Group (2010) Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler 16:1360-1366
16. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, LAQ/5062 Study Group (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371:2085-2092 (Pubitemid 351842581)
17. J Croitoru-Lamoury FMJ Lamoury M Caristo K Suzuki D Walker, et al. 2011 Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO) PLoS ONE 6 e14698 10.1371/journal.pone.0014698 21359206 10.1371/journal.pone.0014698 1:CAS:528:DC%2BC3MXislCntrs%3D
18. MG Espey ON Chernyshev JF Reinhard Jr MA Namboodiri CA Colton 1997 Activated human microglia produce the excitotoxin quinolinic acid Neuroreport 8 431 434 9080423 10.1097/00001756-199701200-00011 1:CAS:528:DyaK2sXisVaisrY%3D (Pubitemid 27180096)
19. F Fallarino U Grohmann C Vacca R Bianchi C Orabona A Spreca, et al. 2002 T cell apoptosis by tryptophan catabolism Cell Death Differ 9 1069 1077 12232795 10.1038/sj.cdd.4401073 1:CAS:528:DC%2BD38XmvFGhtbY%3D
20. O Fernandez 2011 Oral laquinimod treatment is multiple sclerosis Neurologia 26 111 117 21163185 10.1016/j.nrl.2010.07.027
21. EM Flanagan JB Erickson OH Viveros SY Chang JF Reinhard Jr 1995 Neurotoxin quinolinic acid is selectively elevated in spinal cords of rats with experimental allergic encephalomyelitis J Neurochem 64 1192 1196 7861150 10.1046/j.1471-4159.1995.64031192.x 1:CAS:528:DyaK2MXjvVygtbc%3D
22. G Frumento R Rotondo M Tonetti G Damonte U Benatti GB Ferrara 2002 Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase J Exp Med 196 459 468 12186838 10.1084/jem.20020121 1:CAS:528:DC%2BD38XmsV2htLk%3D
23. J Füvesi C Somlai H Németh H Varga Z Kis T Farkas, et al. 2004 Comparative study on the effects of kynurenic acid and glucosamine- kynurenic acid Pharmacol Biochem Behav 77 95 102 14724046 10.1016/j.pbb.2003.10. 001 (Pubitemid 38076985)
24. R Gold L Kappos A Bar-Or D Arnold G Giovannoni K Selmaj, et al. 2011 Clinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trial Mult Scler Suppl 10 34
25. MC Graves M Fiala LA Dinglasan NQ Liu J Sayre, et al. 2004 Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells Amyotroph Lateral Scler Other Motor Neuron Disord 5 213 219 15799549 10.1080/14660820410020286 1:CAS:528:DC%2BD2cXhtFSntrbF (Pubitemid 40125187)
26. P Guidetti L Amori MT Sapko E Okuno R Schwarcz 2007 Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain J Neurochem 102 103 111 17442055 10.1111/j.1471-4159.2007.04556.x 1:CAS:528:DC%2BD2sXnvVWjtb4%3D (Pubitemid 46906272)
27. GJ Guillemin SJ Kerr LA Pemberton DG Smith GA Smythe PJ Armati BJ Brew 2001 IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment J Interferon Cytokine Res 21 1097 1101 11798468 10.1089/107999001317205231 1:CAS:528: DC%2BD38XlsVyqtg%3D%3D (Pubitemid 34114289)
28. GJ Guillemin SJ Kerr GA Smythe, et al. 2001 Kynurenine pathway metabolism in human astrocytes J Neurochem 78 842 853 11520905 10.1046/j.1471-4159.2001. 00498.x 1:CAS:528:DC%2BD3MXmt1egsLc%3D (Pubitemid 32777985)
29. GJ Guillemin V Meininger BJ Brew 2005 Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis Neurodegener Dis 2 166 176 16909022 10.1159/000089622 1:CAS:528:DC%2BD28Xit1Wqsw%3D%3D (Pubitemid 43827918)
30. GJ Guillemin L Wang BJ Brew 2005 Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex J Neuroinflammation 2 16 16042813 10.1186/1742-2094-2-16 (Pubitemid 41522072)
31. Q Han T Cai DA Tagle J Li 2010 Structure, expression, and function of kynurenine aminotransferases in human and rodent brains Cell Mol Life Sci 67 353 368 19826765 10.1007/s00018-009-0166-4 1:CAS:528:DC%2BC3cXis1aqsQ%3D%3D
32. Z Hartai P Klivenyi T Janaky B Penke L Dux L Vecsei 2005 Kynurenine metabolism in multiple sclerosis Acta Neur Scand 112 93 96 10.1111/j.1600-0404. 2005.00442.x 1:CAS:528:DC%2BD2MXos1Crtbg%3D (Pubitemid 41003368)
33. JS Henkel JI Engelhardt L Siklos EP Simpson SH Kim T Pan, et al. 2004 Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue Ann Neurol 55 221 235 14755726 10.1002/ana.10805 1:CAS:528:DC%2BD2cXhs1SgtbY%3D (Pubitemid 38166999)
34. MP Heyes K Saito JS Crowley LE Davis MA Memitrack M Der, et al. 1992 Quinolinic acid and kynurenine pathway metabolism in inflammatory and noninflammatory neurological disease Brain 115 1249 1273 1422788 10.1093/brain/115.5.1249
35. MP Heyes K Saito SP Markey 1992 Human macrophages convert l-tryptophan into the neurotoxin quinolinic acid Biochem J 283 633 635 1534219 1:CAS:528:DyaK38XktVGru7w%3D
36. M Hokari HQ Wu R Schwarcz QR Smith 1996 Facilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid Neuroreport 8 15 18 9051744 10.1097/00001756-199612200-00004 1:CAS:528:DyaK2sXhvFeltb8%3D (Pubitemid 126785523)
37. J Ilzecka T Kocki Z Stelmasiak WA Turski 2003 Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis Acta Neurol Scand 107 412 418 12757473 10.1034/j.1600-0404.2003.00076.x 1:CAS:528:DC%2BD3sXltFGqsrw%3D (Pubitemid 36683472)
38. LD Jacobs DL Cookfair RA Rudick RM Herndon JR Richert AM Salazar, et al. 1996 Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol 39 285 294 8602746 10.1002/ana.410390304 1:CAS:528:DyaK28XisFyrsLY%3D (Pubitemid 26100751)
39. KH Jhamandas RJ Boegman RJ Beninger AF Miranda KA Lipic 2000 Excitotoxicity of quinolinic acid: modulation by endogenous antagonists Neurotoxic Res 2 139 155 10.1007/BF03033790 1:CAS:528:DC%2BD3cXot1Cqsrc%3D
40. JW Johnson P Ascher 1987 Glycine potentiates the NMDA response in cultured mouse brain neurons Nature 325 529 531 2433595 10.1038/325529a0 1:CAS:528:DyaL2sXhtFCju7c%3D (Pubitemid 17056733)
41. KP Johnson BR Brooks JA Cohen CC Ford J Goldstein RP Lisak, et al. 1995 Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 45 1268 1276 7617181 1:STN:280:DyaK2Mzkt1eqtQ%3D%3D
42. R Kanki T Nakamizo H Yamashita T Kihara H Sawada K Uemura, et al. 2004 Effects of mitochondrial dysfunction on glutamate receptor-mediated neurotoxicity in cultured rat spinal motor neurons Brain Res 1015 73 81 15223368 10.1016/j.brainres.2004.04.044 1:CAS:528:DC%2BD2cXlt1Wgtro%3D (Pubitemid 38829738)
43. L Kappos EW Radue P O'Connor C Polman R Hohlfeld P Calabresi FREEDOMS Study Group, et al. 2010 A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 387 401 20089952 10.1056/NEJMoa0909494 1:CAS:528:DC%2BC3cXhvVWltr4%3D
44. WJ Kelly RE Burke 1996 Apoptotic neuron death in rat substantia nigra induced by striatal excitotoxic injury is developmentally dependent Neurosci Lett 220 85 88 8981479 10.1016/S0304-3940(96)13216-X 1:CAS:528: DyaK28XnsFWhu78%3D (Pubitemid 26426590)
45. SJ Kerr PJ Armati BJ Brew 1995 Neurocytotoxicity of quinolinic acid in human brain cultures J Neurovirol 1 375 380 9222380 10.3109/13550289509111027 1:CAS:528:DyaK28XhsFKlt74%3D
46. Kiss C, Vécsei L (2009) Kynurenines in the brain: preclinical and clinical studies, therapeutic considerations. In: Lajtha A (ed) Handbook of neurochemistry and molecular neurobiology, 3rd edn. Springer, Heidelberg, pp 91-105
47. C Kiss G Ceresoli-Borroni P Guidetti CL Zielke HR Zielke R Schwarcz 2003 Kynurenate production by cultured human astrocytes J Neural Transm 110 1 14 12541009 1:CAS:528:DC%2BD3sXltlCitA%3D%3D (Pubitemid 36135551)
48. E Kwidzinski I Bechmann 2007 IDO expression in the brain: a double-edged sword J Mol Med 85 1351 1359 17594069 10.1007/s00109-007-0229-7 (Pubitemid 350234090)
49. E Kwidzinski J Bunse O Aktas D Richter L Mutlu F Zipp, et al. 2005 Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation FASEB J 19 1347 1349 15939737 1:CAS:528:DC%2BD2MXntlaqsb8%3D (Pubitemid 41113745)
50. GK Lee HJ Park M Macleod P Chandler DH Munn AL Mellor 2002 Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division Immunology 107 452 460 12460190 10.1046/j.1365-2567.2002.01526.x 1:CAS:528:DC%2BD38Xps1yqtLs%3D (Pubitemid 36693650)
51. E Lehrmann A Molinari C Speciale R Schwarcz 2001 Immunohistochemical visualization of newly formed quinolate in the normal and excitotoxically lesioned rat striatum Exp Brain Res 141 389 397 11715084 10.1007/s002210100887 1:CAS:528:DC%2BD3MXot1yksLg%3D (Pubitemid 33071184)
52. RA Linker DH Lee S Ryan AM van Dam R Conrad P Bista, et al. 2011 Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway Brain 134 678 692 21354971 10.1093/brain/awq386
53. G Lovas N Szilagyi K Majtenyi M Palkovits S Komoly 2000 Axonal changes in chronic demyelinated cervical spinal cord plaques Brain 123 308 317 10648438 10.1093/brain/123.2.308 (Pubitemid 30055154)
54. FD Lublin SC Reingold 1996 Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis Neurology 46 907 911 8780061 1:STN:280:DyaK28zntlOksg%3D%3D
55. FD Lublin JN Whitaker BH Eidelman AE Miller BG Arnason JS Burks 1996 Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference Neurology 46 12 18 8559358 1:STN:280: DyaK287ktlWmsA%3D%3D (Pubitemid 26157582)
56. A Macaya F Munell RM Gubits RE Burke 1994 Apoptosis in substantia nigra following developmental striatal excitotoxic injury Proc Natl Acad Sci USA 91 8117 8121 7914702 10.1073/pnas.91.17.8117 1:CAS:528:DyaK2cXlsFCku74%3D (Pubitemid 24253897)
57. K Malpass 2011 The kynurenine pathway-promising new targets and therapies for neurodegenerative disease Nat Rev Neurol 7 417 21788979 10.1038/nrneurol.2011.102
58. Mándi Y, Vécsei L (2011) The kynurenine system and immunoregulation. J Neural Transm. doi: 10.1007/s00702-011-0681-y (online first™)
59. M Marosi D Nagy T Farkas Z Kis E Rózsa H Robotka, et al. 2010 A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study J Neural Transm 117 183 188 19953278 10.1007/s00702-009-0346-2 1:CAS:528:DC%2BC3cXpslWjtg%3D%3D
60. M Matysiak M Stasiołek W Orłowski A Jurewicz S Janczar CS Raine K Selmaj 2008 Stem cells ameliorate EAE via an indoleamine 2,3-dioxygenase (IDO) mechanism J Neuroimmunol 193 12 23 18077006 10.1016/j.jneuroim.2007.07. 025 1:CAS:528:DC%2BD1cXlvVGisg%3D%3D
61. PL McGeer EG McGeer 2002 Inflammatory processes in amyotrophic lateral sclerosis Muscle Nerve 26 459 470 12362410 10.1002/mus.10191 1:CAS:528:DC%2BD38Xot1Ggs7Y%3D
62. DH Miller OA Khan WA Sheremata LD Blumhardt GP Rice MA Libonati International Natalizumab Multiple Sclerosis Trial Group, et al. 2003 A controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 348 15 23 12510038 10.1056/NEJMoa020696 1:CAS:528:DC%2BD3sXhtlCntg%3D%3D (Pubitemid 36026342)
63. F Monaco S Fumero A Mondino R Mutani 1979 Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases J Neurol Neurosurg Psychiatry 42 640 641 479903 10.1136/jnnp.42.7.640 1:CAS:528:DyaE1MXltlymur8%3D (Pubitemid 9187862)
64. DH Munn M Zhou JT Attwood, et al. 1998 Prevention of allogenic fetal rejection by tryptophan catabolism Science 281 1122 1124 10.1126/science.281. 5380.1191
65. E Okuno M Nakamura R Schwarcz 1991 Two kynurenine aminotransferases in human brain Brain Res 542 307 312 2029638 10.1016/0006-8993(91)91583-M 1:CAS:528:DyaK3MXhs1Wgtr0%3D
66. PY Paterson 1980 Experimental allergic encephalomyelitis and autoimmune disease Prog Clin Biol Res 49 19 36 6163162 1:CAS:528:DyaL3MXhtlOmsbw%3D
67. DW Paty DK Li 1993 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group Neurology 43 662 667 8469319 1:STN:280: DyaK3s3is1Sqtw%3D%3D (Pubitemid 23121952)
68. M Platten PP Ho S Youssef P Fontoura H Garren EM Hur, et al. 2005 Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite Science 310 850 855 16272121 10.1126/science.1117634 1:CAS:528: DC%2BD2MXhtFKksLbJ (Pubitemid 41567343)
69. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, Laquinimod in Relapsing MS Study Group (2005) Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64:987-991 (Pubitemid 40388448)
70. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al, AFFIRM Investigators (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
71. C Prescott AM Weeks KJ Staley KM Partin 2006 Kynurenic acid has a dual action on AMPA receptor responses Neurosci Lett 402 109 112 10.1016/j.neulet. 2006.03.051 (Pubitemid 43766458)
72. PRISMS Study Group 1998 Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group Lancet 352 1498 1504 10.1016/S0140-6736(98) 03334-0 (Pubitemid 28512925)
73. C Rajda J Bergquist L Vecsei 2007 Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis J Neural Transm Suppl 72 323 329 17982910 10.1007/978-3-211-73574-9-40 1:CAS:528:DC%2BD2sXhsVKns7bF
74. AT Reder G Ebers G Cutter M Kremenchutzky D Goodin J Oger, et al. 2010 Survival analysis 21 years after the initiation of the pivotal interferon beta-1b trial in patients with RRMS Mult Scler 16 S318
75. AT Reder GC Ebers A Traboulsee D Li D Langdon DS Goodin, et al. 2010 Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS Neurology 74 1877 1885 20530324 10.1212/WNL. 0b013e3181e240d0 1:CAS:528:DC%2BC3cXntF2gtb8%3D
76. K Rejdak H Bartosik-Psujek B Dobosz T Kocki P Grieb G Giovannoni, et al. 2002 Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients Neurosci Lett 331 63 65 12359324 10.1016/S0304-3940(02)00710-3 1:CAS:528:DC%2BD38XnsVajuro%3D (Pubitemid 35279383)
77. K Rejdak A Petzold T Kocki J Kurzepa P Grieb WA Turski Z Stelmasiak 2007 Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis J Neural Transm 114 1011 1015 17393066 10.1007/s00702-007-0667-y 1:CAS:528:DC%2BD2sXotFWrsbc%3D (Pubitemid 47106447)
78. C Rios A Santamaria 1991 Quinolinic acid is a potent lipid peroxidant in rat brain homogenates Neurochem Res 16 1139 1143 1686636 10.1007/BF00966592 1:CAS:528:DyaK3MXmsFehtbw%3D
79. H Robotka H Németh C Somlai L Vécsei J Toldi 2005 Systemically administered glucosamine-kynurenic acid, but not pure kynurenic acid, is effective in decreasing the evoked activity in area CA1 of the rat hippocampus Eur J Pharmacol 513 75 80 15878711 10.1016/j.ejphar.2005.02.043 1:CAS:528:DC%2BD2MXjvVOhtr4%3D (Pubitemid 40692248)
80. Ropper AH, Samuels MA (2009) Adams and Victor's principles of neurology, 9th edn. McGraw Hill, New York, pp 1011-1080
81. E Rozsa H Robotka L Vecsei J Toldi 2008 The Janus-face kynurenic acid J Neural Transm 115 1087 1091 18446262 10.1007/s00702-008-0052-5 1:CAS:528:DC%2BD1cXht1ShurjO
82. RA Rudick E Fisher JC Lee J Simon L Jacobs 1999 Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group Neurology 53 1698 1704 10563615 1:STN:280:DC%2BD3c%2FisFWguw%3D%3D (Pubitemid 29530342)
83. SA Sargsyan PN Monk PJ Shaw 2005 Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis Glia 51 241 253 15846792 10.1002/glia.20210 (Pubitemid 41532100)
84. K Sas H Robotka J Toldi L Vécsei 2007 Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders J Neurol Sci 257 221 239 17462670 10.1016/j.jns.2007.01.033 1:CAS:528:DC%2BD2sXmtlWgurw%3D (Pubitemid 46856508)
85. JH Simon LD Jacobs M Campion K Wende N Simonian DL Cookfair, et al. 1998 Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group Ann Neurol 43 79 87 9450771 10.1002/ana.410430114 1:STN:280:DyaK1c7htFantQ%3D%3D (Pubitemid 28124651)
86. O Spreux-Varoquaux G Bensimon L Lacomblez F Salachas PF Pradat N LeForestier, et al. 2002 Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients J Neurol Sci 193 73 78 11790386 10.1016/S0022-510X(01)00661-X 1:CAS:528:DC%2BD38XktFaruw%3D%3D (Pubitemid 34098937)
87. TW Stone 1993 Neuropharmacology of quinolinic and kynurenic acids Pharmacol Rev 45 310 379
88. TW Stone 2000 Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection Tips 21 149 154 10740291 1:CAS:528:DC%2BD3cXisFGgsL0%3D (Pubitemid 30190140)
89. TW Stone 2001 Endogenous neurotoxins from tryptophan Toxicon 39 61 73 10936623 10.1016/S0041-0101(00)00156-2 1:CAS:528:DC%2BD3cXmsFKisr0%3D (Pubitemid 30628929)
90. TW Stone 2001 Kynurenic acid antagonists and kynurenine pathway inhibitors Exp Opin Investig Drugs 10 633 645 10.1517/13543784.10.4.633 1:CAS:528:DC%2BD3MXis1Kjsrg%3D (Pubitemid 32288182)
91. RG Tavares CI Tasca CE Santos M Wajner DO Souza CS Dutra-Filho 2000 Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain Neuroreport 11 249 253 10674464 10.1097/00001756-200002070-00005 1:CAS:528:DC%2BD3cXhtVWhuro%3D (Pubitemid 30074627)
92. The IFNB Multiple Sclerosis Study Group 1993 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology 43 655 661
93. SR Thomas PK Witting R Stocker 1996 3-Hydroxyanthranilic acid is an efficient, cell derived co-antioxidant for α-tocopherol, inhibiting human low density lipoprotein and plasma lipid peroxidation J Biol Chem 271 32714 32721 8955104 10.1074/jbc.271.51.32714 1:CAS:528:DyaK2sXmvVOg (Pubitemid 27008696)
94. E Vamos A Pardutz P Klivenyi J Toldi L Vecsei 2009 The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection J Neurol Sci 283 21 27 19268309 10.1016/j.jns.2009.02.326 1:CAS:528:DC%2BD1MXoslSitr8%3D
95. L Vécsei J Miller U MacGarvey MF Beal 1992 Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain Brain Res Bull 28 233 238 1596743 10.1016/0361-9230(92)90184-Y
96. AM Vincent C Backus AA Taubman EL Feldman 2005 Identification of candidate drugs for the treatment of ALS Amyotroph Lateral Scler 6 29 36 10.1080/14660820510026171 1:CAS:528:DC%2BD2MXjvFWqur4%3D (Pubitemid 40668245)
97. WO Whetsell R Schwarcz 1989 Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system Neurosci Lett 97 271 275 2524015 10.1016/0304-3940(89)90609-5 1:CAS:528:DyaL1MXhtlSisr0%3D (Pubitemid 19047470)
98. P Yu Z Li L Zhang DA Tagle T Cai 2006 Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family Gene 365 111 118 16376499 10.1016/j.gene.2005.09.034 1:CAS:528: DC%2BD28Xht1CkurY%3D (Pubitemid 43185231)
99. D Zádori G Nyiri A Szonyi I Szatmári F Fülöp J Toldi, et al. 2011 Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease J Neural Transm 118 865 875 21194001 10.1007/s00702-010-0573-6
100. D Zádori P Klivényi I Plangár J Toldi L Vécsei 2011 Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines J Cell Mol Med 15 701 717 21155972 10.1111/j.1582-4934.2010.01237.x